Difference between revisions of "Tivozanib (Fotivda)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://ascopubs.org/doi/full/10.1200" to "https://doi.org/10.1200") |
m |
||
Line 2: | Line 2: | ||
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=561728 NCI Drug Dictionary]: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. | From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=561728 NCI Drug Dictionary]: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. | ||
− | = | + | =Diseases for which it is used= |
+ | *[[Renal cell carcinoma]] | ||
− | == | + | ==History of changes in FDA approval== |
− | + | ''Not currently FDA approved for any indication.'' | |
− | |||
==Also known as== | ==Also known as== | ||
*'''Code name:''' AV-951 | *'''Code name:''' AV-951 | ||
+ | *'''Brand name:''' Fotivda | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
− | |||
[[Category:VEGFR inhibitors]] | [[Category:VEGFR inhibitors]] | ||
+ | |||
+ | [[Category:Renal cell carcinoma medications]] | ||
+ | |||
+ | [[Category:EMA approved drugs]] |
Revision as of 00:47, 17 February 2021
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.
Diseases for which it is used
History of changes in FDA approval
Not currently FDA approved for any indication.
Also known as
- Code name: AV-951
- Brand name: Fotivda